Post-translational modifications in the context of therapeutic proteins

GR Walsh, Royston Jefferis

Research output: Contribution to journalReview article

651 Citations (Scopus)


The majority of protein-based biopharmaceuticals approved or in clinical trials bear some form of post-translational modification (PTM), which can profoundly affect protein properties relevant to their therapeutic application. Whereas glycosylation represents the most common modification, additional PTMs, including carboxylation, hydroxylation, sulfation and amidation, are characteristic of some products. The relationship between structure and function is understood for many PTMs but remains incomplete for others, particularly in the case of complex PTMs, such as glycosylation. A better understanding of such structural-functional relationships will facilitate the development of second-generation products displaying a PTM profile engineered to optimize therapeutic usefulness.
Original languageEnglish
Pages (from-to)1241-1252
Number of pages12
JournalNature Biotechnology
Issue number10
Publication statusPublished - 1 Oct 2006


Dive into the research topics of 'Post-translational modifications in the context of therapeutic proteins'. Together they form a unique fingerprint.

Cite this